Cover Image
市場調查報告書

速放性疼痛管理的預測

Immediate Release Pain Management to 2020

出版商 Greystone Research Associates 商品編碼 302703
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
速放性疼痛管理的預測 Immediate Release Pain Management to 2020
出版日期: 2014年05月21日 內容資訊: 英文
簡介

在先進地區的壽命延長,高齡化進行中,慢性疼痛及急性疼痛的罹患率、得病率也增加,從患者和家族生活品質的觀點來看,對疼痛管理有高度關注。因應這個趨勢,醫藥品開發經營者,以疼痛管理藥品的新製劑化為焦點。經粘膜的疼痛管理,可能改善服藥遵守,對應在高齡化和經濟發展中特別成為問題的重要醫療課題。本市場,吸收性固體給藥技術已應用於現有藥物,在類似製劑成為新疼痛管理藥重要給藥途徑之下,預測到2020年將達成強勢成長。

本報告提供速放性疼痛管理藥的市場相關調查、人口動態、得病率等市場環境與市場機會、速放性製劑的各種技術、主要產品的藥物簡介、市場上的地位、收益預測、新產品的開發情形、法律規章等的市場的各種影響因素分析等彙整。

摘要整理

疼痛管理市場

  • 進化的疼痛管理通訊協定
  • 人口動態與疾病
  • 疼痛管理的地區性差異
  • 速放性疼痛管理
  • 癌症突發性疼痛
  • 目前環境
  • 未滿足需求與市場機會

速放性製劑技術

  • 口頰片、口含錠
  • 口腔噴霧
  • 舌下含片
  • 鼻噴霧

癌症突發性疼痛市場

  • 支援市場
  • 人口動態和成長率
  • 競爭的藥物類別
  • 市場預測

產品分析、市場上地位、收益的轉變與預測

  • 粘膜速放性Fentanyl(TIRF:Transmucosal immediate-release fentanyl)
  • 口服藥
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • 非專利速放性Fentanyl
  • 鼻腔藥
  • Instanyl
  • Lazanda

開發階段的IR疼痛管理藥

  • Alfentanil
  • Sufentanil
  • 潛在性競爭藥物治療

市場係數

  • 法律規章
  • 獨自製劑及技術
  • 聯盟、聯盟

企業簡介

目錄
Product Code: PMP492R

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to alternative formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, transmucosal pain management addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. We expect this market to experience healthy growth through 2020 as absorbable solid dosage technology is applied to existing drugs, and as similar formulations become an important route of administration for novel pain drugs

Highlights

  • Analyzes and evaluates the global market opportunity for immediate release pain management and assesses the probable impact of evolving regulatory, economic and demand factors
  • Assesses immediate release products approved or in development for the delivery of therapeutic pain management drugs
  • Provides detailed descriptions of pain management treatment segments, market factors, and business strategies
  • Forecasts immediate release pain management product demand to 2020
  • Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners

Table of Contents

  • Executive Summary
  • The Pain Management Market
  • Evolving Pain Management Protocols
  • Demographics and Disease
  • Regional Differences in Pain Management
  • Immediate Release Pain Management
  • Breakthrough Cancer Pain
  • The Current Landscape
  • The Unmet Need and Opportunity
  • Immediate Release Formulation Technologies
  • Buccal Films and Tablets
  • Oral Sprays
  • Sublingual Tablets
  • Nasal Sprays
  • The Market for Breakthrough Cancer Pain
  • The Addressable Market
  • Market Demographics and Growth
  • Competing Drug Classes
  • Market Projections
  • Product Analysis, Market Position Historical Revenue & Forecasts
  • Transmucosal Immediate-Release Fentanyl (TIRF)
  • Oral
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • Generic Immediate Release Fentanyl
  • Nasal
  • Instanyl
  • Lazanda
  • Development-Stage IR Pain Management Drugs
  • Alfentanil
  • Sufentanil
  • Potential Competing Drug Therapeutics
  • Market Factors
  • Regulatory Factors
  • Proprietary Formulations & Technology
  • Collaborations & Alliances
  • Company Profiles
Back to Top